Fig. 1: MCT increases T - myeloid cell spatial proximity.

a MTD = Maximum tolerated Dose and MCT = Metronomic Dose. Box plots show tumor burden on Day 28 relative to Day 0 of treatment in MMTV-neu (left), C3-1-TAg (center), and MMTV-PyMT (right) mice. b PFS (%) indicates the tumor volume doubling time in MMTV-neu (left), C3-1-TAg (center), and MMTV-PyMT (right) (generated using the Survimer R package, log rank p-value). a, Immunofluorescence b 3–5 mice pooled over three cohorts (n = 10–13 per group). c Representative IF images of C3-1-TAg breast tumor tissues stained with Iba1, CD3, and DAPI. Box plots quantify spatial proximity (right) (n = 9 slides per group). d Representative IF images of MMTV-PyMT breast tumor tissues stained with Iba1, CD8, and DAPI. Box plots quantify Iba1⁺ and CD8⁺ cell spatial proximity (n = 5–8 slides per group). e CyTOF data t-SNE plots compare CD11c expression in MMTV-neu and C3-1-TAg tumors upon treatment with either Vehicle, MTD, or MCT. f Biaxial plots (left) compare and box plots (right) quantify the mean percentage of CD11c⁺ I-A-I-E⁺ cells among all the CD45⁺ cells identified using CyTOF. In e, f CYTOF data, n = 1 million events per mouse (2 mice per group). g Gating strategy of DC-OT-ǀ T cells co-culture assay. h Box plots show percentage of CD8⁺ T cells in division phases 0 to 3+ in different treatment strategies upon co-culture with tumor-infiltrating DCs. i Analysis of IFN-γ in OT-ǀ T cells after co-culture. h, i 3–5 mice pooled over two cohorts (n = 3 to 10 per group). a–i In box plots, error bar = Mean ± SEM, center = Means (Diamonds) and Medians (Line), bottom and top boundaries of the box = 25 and 75th percentiles of the data, minima and maxima = lowest and highest data points, and two-sided T-test p-values.